Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement-119.26 M136.13 M-114.33 M90.91 M-177.6 M69.76 M77.47 MFlux de trésorerie liés aux activités de financement12.21 M-302.59 M-17.28 M-148.72 M-28.35 M-220.37 M-179.8 MFlux de trésorerie disponible151.97 M167.89 M120.32 M127.04 M198.07 M141.78 M120.15 M
Corcept Therapeutics Incorporated - Common Stock
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.